Lingli Chen
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery
Papers in
- Oncology 23
- Cancer Immunotherapy and Biomarkers 6
- Cancer Cells and Metastasis 4
- Hepatology 11
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Co-authors
- Yaping Li (13 shared papers)Haijun Yu (12 shared papers)Qi Yin (9 shared papers)Wangwen Gu (11 shared papers)Zhiwen Zhang (10 shared papers)Qingshuo Meng (7 shared papers)Jinghan Su (6 shared papers)Huiping Sun (5 shared papers)
- Journals
- Advanced Functional Materials (5 papers)Journal of the American Heart Association (3 papers)Abdominal Radiology (3 papers)Cancer Immunology Immunotherapy (3 papers)Cancer Management and Research (3 papers)
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Lingli Chen
117 papers receiving 4.8k citations
Lingli Chen's Hit Papers
Peers
Comparison fields: 5 of 137
- Hepatology 455
- Biomaterials 780
- Geriatrics and Gerontology 126
- Oncology 688
- Cancer Research 355
Countries citing papers authored by Lingli Chen
This map shows the geographic impact of Lingli Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingli Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingli Chen more than expected).
Fields of papers citing papers by Lingli Chen
This network shows the impact of papers produced by Lingli Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingli Chen. The network helps show where Lingli Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Lingli Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors Hit paper breakdown → | 2016 | 581 |
| 2 | 2016 | 329 | |
| 3 | 2019 | 306 | |
| 4 | 2018 | 235 | |
| 5 | 2012 | 214 | |
| 6 | 2021 | 188 | |
| 7 | 2015 | 137 | |
| 8 | The Interaction between Flavonoids and Intestinal Microbes: A Review Hit paper breakdown → | 2023 | 136 |
| 9 | 2014 | 116 | |
| 10 | 2013 | 114 | |
| 11 | 2015 | 110 | |
| 12 | 2012 | 100 | |
| 13 | 2018 | 98 | |
| 14 | 2020 | 94 | |
| 15 | 2021 | 92 | |
| 16 | 2016 | 90 | |
| 17 | 2015 | 89 | |
| 18 | 2017 | 67 | |
| 19 | 2018 | 64 | |
| 20 | 2011 | 61 |
About Lingli Chen
Lingli Chen is a scholar working on Oncology, Hepatology, Biomaterials, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 121 papers that have together received 4.9k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Nanoparticle-Based Drug Delivery (10 papers), Nanoplatforms for cancer theranostics (8 papers), Cancer Immunotherapy and Biomarkers (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Advanced biosensing and bioanalysis techniques (6 papers), Cancer, Lipids, and Metabolism (5 papers) and Cancer Cells and Metastasis (4 papers). The work is most often cited by research in Hepatology (455 citations), Biomaterials (780 citations), Geriatrics and Gerontology (126 citations), Oncology (688 citations) and Cancer Research (355 citations). Lingli Chen has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Yaping Li, Haijun Yu, Qi Yin, Wangwen Gu, Zhiwen Zhang, Qingshuo Meng, Jinghan Su, Huiping Sun, Yuan Ji and Pengcheng Zhang. Their work appears in journals such as Advanced Functional Materials, Journal of the American Heart Association, Abdominal Radiology, Cancer Immunology Immunotherapy and Cancer Management and Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.